Novartis biosimilars news

Novartis’ Sandoz Inc. unit said it plans to launch five biosimilars worldwide by 2020. The planned launches include GP2015, a biosimilar of autoimmune drug Enbrel etanercept; LA-EP2006, a biosimilar of neutropenia drug Neulasta pegfilgrastim; GP2013 a biosimilar of autoimmune and cancer drug Rituxan rituximab; GP2017, a biosimilar of autoimmune drug Humira adalimumab; and GP 1111, a biosimilar of autoimmune drug Remicade infliximab. Regulatory applications are already under review in the U.S. and EU for GP2015 and LA-EP2006 and in the EU for GP2013. Sandoz said it plans to submit the remaining five regulatory applications in the U.S. and EU by the end of 2017. ...